Truist Financial Cuts Pediatrix Medical Group (NYSE:MD) Price Target to $15.00

Pediatrix Medical Group (NYSE:MD) had its price target dropped by equities researchers at Truist Financial from $16.00 to $15.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s price target suggests a potential upside of 14.16% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. StockNews.com cut Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday, December 19th. Jefferies Financial Group boosted their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Mizuho boosted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Finally, Macquarie began coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Pediatrix Medical Group has an average rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Trading Up 0.8 %

Shares of NYSE MD opened at $13.14 on Monday. The business has a 50 day simple moving average of $14.35 and a 200 day simple moving average of $11.45. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -4.29, a PEG ratio of 2.00 and a beta of 1.58. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.29 earnings per share. On average, research analysts predict that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In related news, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors have recently made changes to their positions in MD. Ballentine Partners LLC acquired a new stake in Pediatrix Medical Group in the 2nd quarter valued at $132,000. Texas Permanent School Fund Corp grew its stake in Pediatrix Medical Group by 29.6% in the second quarter. Texas Permanent School Fund Corp now owns 93,367 shares of the company’s stock valued at $705,000 after purchasing an additional 21,351 shares in the last quarter. ClariVest Asset Management LLC bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $1,721,000. American Century Companies Inc. boosted its holdings in shares of Pediatrix Medical Group by 13.7% in the 2nd quarter. American Century Companies Inc. now owns 124,395 shares of the company’s stock valued at $939,000 after buying an additional 15,023 shares during the last quarter. Finally, WINTON GROUP Ltd lifted its stake in Pediatrix Medical Group by 33.9% in the second quarter. WINTON GROUP Ltd now owns 130,491 shares of the company’s stock valued at $985,000 after acquiring an additional 33,057 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.